HC Wainwright Comments on Ocugen’s Q1 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Ocugen in a report issued on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.05) per share for the quarter, up from their prior forecast of ($0.06). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.18 EPS, FY2029 earnings at $0.84 EPS and FY2030 earnings at $1.79 EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The firm had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.86 million.

A number of other equities research analysts have also recently commented on OCGN. Oppenheimer assumed coverage on Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Canaccord Genuity Group started coverage on Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Ocugen in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.75.

Ocugen Trading Down 4.6%

Shares of Ocugen stock opened at $1.87 on Friday. Ocugen has a fifty-two week low of $0.57 and a fifty-two week high of $2.73. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $613.17 million, a P/E ratio of -8.13 and a beta of 2.75. The company has a fifty day moving average of $1.74 and a 200 day moving average of $1.54.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Ocugen in the fourth quarter worth about $106,000. Tower Research Capital LLC TRC grew its holdings in Ocugen by 208.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 72,776 shares of the company’s stock valued at $71,000 after buying an additional 49,177 shares in the last quarter. Creative Planning purchased a new position in Ocugen during the 2nd quarter valued at approximately $57,000. Schonfeld Strategic Advisors LLC bought a new stake in Ocugen in the 4th quarter worth approximately $38,000. Finally, NewEdge Advisors LLC increased its stake in Ocugen by 198.0% in the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after acquiring an additional 24,460 shares during the last quarter. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Key Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly EPS forecasts (Q1–Q4 moved toward ($0.05) from ($0.06)), boosted FY2026 and materially raised long‑range revenue/earnings assumptions (FY2028–FY2030), and reiterated a “Buy” rating with a $10 price target — a constructive analyst endorsement that supports longer‑term upside. HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price
• Positive Sentiment: Chardan Capital assigned a Buy rating on Ocugen, adding another buy‑side vote that may attract momentum buyers or traders looking for analyst‑driven catalysts. Ocugen (NASDAQ:OCGN) Earns Buy Rating from Chardan Capital
• Neutral Sentiment: Consensus for FY2026 EPS remains negative (around ($0.20) per share), so while some analysts are lifting estimates, the market still expects a loss this year — keeping Ocugen in speculative/biotech territory.
• Negative Sentiment: Noble Financial lowered near‑term EPS estimates (Q3 2026 to ($0.07) and Q4 2026 to ($0.08); FY2026 to ($0.26)), signaling concern about near‑term performance and adding selling pressure from cautious shops.
• Negative Sentiment: Clinical setback: Phase II data for OCU410 in an eye disease trial showed lower lesion reduction versus earlier results (despite a reported 31% improvement), which triggered the immediate stock weakness as investors reassess clinical and regulatory risk. Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.